Sarolaner
 | |
| Clinical data | |
|---|---|
| Trade names | Simparica |
| Other names | PF-6450567 |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.234.000 |
| Chemical and physical data | |
| Formula | C23H18Cl2F4N2O5S |
| Molar mass | 581.36 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sarolaner, sold under the brand name Simparica, is an ectoparasiticide veterinary medication for the treatment of flea and tick infestations in dogs.[7][8] It is also used off-label to control sarcoptic mange and demodectic mange.[8]
Sarolaner is also a component of the combination drug Simparica Trio, which contains sarolaner, moxidectin, and pyrantel.[9][10] It is used for prevention of heartworm disease caused by Dirofilaria immitis; treat and prevent flea infestations; treat and control tick infestations with the lone star tick, Gulf Coast tick, American dog tick, black-legged tick, and brown dog tick; and treat and control roundworm and adult hookworm infections.[11]
Sarolaner is also an ingredient in feline combination antiparasitic Revolution Plus (or Stronghold Plus[12]), which contains sarolaner and selamectin and is used for prevention of sarcoptic mange, feline hookworms, feline roundworms, ear mites, and heartworms, as well as treating and preventing fleas and ticks.[13]
References
[edit]- ^ "Notice: Prescription Drug List (PDL): Multiple additions [2016-08-09]". Health Canada. 9 August 2016. Retrieved 10 July 2024.
- ^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Archived from the original on 17 April 2024. Retrieved 10 July 2024.
- ^ "Drug and medical device highlights 2019: Helping you maintain and improve your health". Health Canada. 18 November 2020. Retrieved 10 July 2024.
- ^ "Simparica". U.S. Food and Drug Administration (FDA). Archived from the original on 10 July 2024. Retrieved 12 December 2022.
- ^ "Simparica EPAR". European Medicines Agency. 18 December 2015. Archived from the original on 10 July 2024. Retrieved 13 June 2024.
- ^ "MiPet Easecto EPAR". European Medicines Agency. 23 February 2018. Archived from the original on 10 July 2024. Retrieved 13 June 2024.
- ^ McTier TL, Chubb N, Curtis MP, Hedges L, Inskeep GA, Knauer CS, et al. (May 2016). "Discovery of sarolaner: A novel, orally administered, broad-spectrum, isoxazoline ectoparasiticide for dogs" (PDF). Veterinary Parasitology. 222: 3–11. doi:10.1016/j.vetpar.2016.02.019. PMID 26961590. Archived (PDF) from the original on 4 November 2020. Retrieved 13 March 2022.
- ^ a b Gollakner R. "Sarolaner". vcahospitals.com. VCA Hospitals. Archived from the original on 27 June 2021. Retrieved 26 June 2021.
- ^ "Simparica Trio". U.S. Food and Drug Administration (FDA). Archived from the original on 9 December 2022. Retrieved 12 December 2022.
- ^ "Simparica Trio EPAR". European Medicines Agency. 14 October 2019. Archived from the original on 15 June 2024. Retrieved 15 June 2024.
- ^ "FDA Approves Simparica Trio, a Combination Drug for Heartworm and Other Parasites". U.S. Food and Drug Administration (FDA). 2 March 2020. Archived from the original on 24 September 2021. Retrieved 26 June 2021.
- ^ "Stronghold Plus". European Medicines Agency. 9 March 2017. Archived from the original on 10 July 2024. Retrieved 12 December 2022.
- ^ "Revolution Plus". U.S. Food and Drug Administration (FDA). Archived from the original on 10 July 2024. Retrieved 12 December 2022.
 | This veterinary medicine–related article is a stub. You can help Wikipedia by expanding it. |
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |